As of 2025-05-17, the Intrinsic Value of InterCure Ltd (INCR.TA) is 1,236.28 ILS. This INCR.TA valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 549.60 ILS, the upside of InterCure Ltd is 124.90%.
The range of the Intrinsic Value is (15.48) - 4,738.69 ILS
Based on its market price of 549.60 ILS and our intrinsic valuation, InterCure Ltd (INCR.TA) is undervalued by 124.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (41,775.16) - (3,172.42) | (6,084.42) | -1207.1% |
| DCF (Growth 10y) | (4,963.74) - (121,655.35) | (12,149.98) | -2310.7% |
| DCF (EBITDA 5y) | (15.48) - 4,738.69 | 1,236.28 | 124.9% |
| DCF (EBITDA 10y) | (750.52) - 36,620.46 | 4,634.85 | 743.3% |
| Fair Value | -3,008.32 - -3,008.32 | -3,008.32 | -647.37% |
| P/E | (1,817.02) - (1,817.02) | (1,820.03) | -431.2% |
| EV/EBITDA | (350.07) - 659.33 | 121.19 | -77.9% |
| EPV | (9.83) - 712.75 | 351.46 | -36.1% |
| DDM - Stable | (865.35) - (2,268.34) | (1,566.85) | -385.1% |
| DDM - Multi | (767.01) - (1,611.21) | (1,044.40) | -290.0% |
| Market Cap (mil) | 259.71 |
| Beta | 1.67 |
| Outstanding shares (mil) | 0.47 |
| Enterprise Value (mil) | 349.61 |
| Market risk premium | 6.13% |
| Cost of Equity | 11.25% |
| Cost of Debt | 42.16% |
| WACC | 24.78% |